Hoosier Cancer Research Network on Facebook

Hoosier Cancer Research Network on Facebook

OnCore Login
Login to Oncore Network

Login to Oncore Network

Hoosier Cancer Research Network on Facebook

Hoosier Cancer Research Network on Facebook

University of North Carolina Lineberger Comprehensive Cancer Center

Chapel Hill, NC

UNC Lineberger Comprehensive Cancer Center is a cancer research and treatment center at the University of North Carolina at Chapel Hill. Serving patients at the N.C. Cancer Hospital, UNC Lineberger is the only public comprehensive cancer center in the state of North Carolina.

One of the leading cancer centers in the nation, UNC Lineberger Comprehensive Cancer Center is located in Chapel Hill, North Carolina. As one of only 51 National Cancer Institute-designated Comprehensive Cancer Centers, UNC Lineberger was rated as exceptional – the highest category – by the National Cancer Institute. The center brings together some of the most exceptional physicians and scientists in the country to investigate and improve the prevention, early detection and treatment of cancer.

With research that spans the spectrum from the laboratory to the bedside to the community, UNC Lineberger faculty work to understand the causes of cancer at the genetic and environmental levels, to conduct groundbreaking laboratory research, and to translate findings into pioneering and innovative clinical trials.

Website: UNC Lineberger Comprehensive Cancer Center

Contact:

919-966-3036

Trials at this location:

HCRN-AML20-472

TAGALONG Trial: Phase II Study of TAGraxofusp and Azacitidine With or Without Venetoclax in Newly Diagnosed Secondary AML after Previous Exposure to HypOmethylatiNG Agents

Status: Open to Accrual
Read More

HCRN-BRE18-360

Phase I/II Study of Stereotactic Radiosurgery With Concurrent Administration of DNA Damage Response (DDR) Inhibitor (OLAparib) Followed by Adjuvant Combination of DuRvalumab (MEDI4736) and Physician’s Choice Systemic Therapy in Subjects With BreAst Cancer Brain Metastases

Status: Open to Accrual
Read More

HCRN-BSK22-562

Observational basket trial to predict response to immune checkpoint inhibitors across solid tumors using a live tumor diagnostic platform (CYBRID-02)

Status: Open to Accrual
Read More

TBCRC047

Innovative Combination Immunotherapy for Metastatic Triple Negative Breast Cancer (TNBC): A Multicenter, Multi-Arm Translational Breast Cancer Research Consortium Study

Status: Open to Accrual
Read More